Saifuldeen Al Qaisi, MD
Interventional Cardiology · Peoria, AZNPI 1053673723
Payments from drug & device makers
Across 368 payments — averaging $72.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$6K
- Philips North America LLC$5K
- Boston Scientific$5K
- Abbott$3K
- Abiomed$2K
- Kestra Medical Technology Services, Inc.$1K
- plus $5K from 25 others
What the payments were for
- Consulting fees$1,8807%
- Travel & lodging$9,53436%
- Food & beverage$15,36457%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 53 | $6,051 |
| Philips North America LLC | 45 | $5,349 |
| Boston Scientific | 45 | $4,701 |
| Abbott | 23 | $2,628 |
| Abiomed | 28 | $1,703 |
| Kestra Medical Technology Services, Inc. | 48 | $1,177 |
| Shockwave Medical, Inc | 7 | $1,019 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 17 | $892 |
| Amgen | 31 | $759 |
| Johnson & Johnson | 8 | $268 |
| Biosense Webster, Inc. | 8 | $258 |
| Inari Medical, Inc. | 9 | $249 |
| Edwards Lifesciences | 3 | $226 |
| Cvrx, Inc. | 1 | $176 |
| Impulse Dynamics (USA) Inc. | 1 | $152 |
| Inspire Medical Systems, Inc. | 1 | $150 |
| Amarin Pharma, Inc. | 2 | $135 |
| Novartis | 6 | $127 |
| AstraZeneca | 4 | $115 |
| Chiesi USA, Inc. | 7 | $112 |
| Penumbra, Inc. | 2 | $93 |
| Bard Peripheral Vascular, Inc. | 3 | $89 |
| Boehringer Ingelheim | 3 | $66 |
| Stryker | 2 | $63 |
| Actelion Pharmaceuticals US, Inc. | 2 | $49 |
| Sanofi-aventis U.S. LLC | 2 | $39 |
| Imperative Care, Inc | 1 | $31 |
| Pfizer | 2 | $30 |
| E.r. Squibb & Sons, L.L.C. | 2 | $30 |
| Novo Nordisk | 1 | $24 |
| Bayer | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Micra$1,898
- (9520) IGT Devices Undivided$1,880
- Advisa$1,491
- TurboHawk$1,254
- VersaCross Access Solution$1,110
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$962
- VersaCross Connect LAAC Access Solution$899
- AVEIR$856
- (6571) Eagle Eye$820
- (6574) Coronary Other$636
- AMPLATZER TALISMAN$622
- Impella$596
- LifeVest$561
- AMPLATZER PICCOLO$541
- Assure WCD$492
- WATCHMAN FLX$427
- OPTIMIZER$303
- (6371) Laser CVX300$258
- Repatha$238
- AngioSculpt CV RX$237
How this compares
$26,778 in reported general payments places this provider in the 65th percentile of 223 interventional cardiology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 102 | $86,459 |
| BrilintaTicagrelor | 60 | $51,036 |
| XareltoRivaroxaban | 29 | $37,420 |
| FarxigaDapagliflozin Propanediol | 34 | $35,928 |
| EntrestoSacubitril/Valsartan | 26 | $24,617 |
| JardianceEmpagliflozin | 12 | $15,668 |
| Repatha SureclickEvolocumab | 11 | $5,929 |
| Bumetanide | 130 | $2,439 |
| Amiodarone Hcl | 60 | $2,177 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 158 | $2,162 |
| Ranolazine ErRanolazine | 25 | $1,908 |
| Metoprolol Succinate | 160 | $1,834 |
| ClopidogrelClopidogrel Bisulfate | 153 | $1,571 |
| Rosuvastatin Calcium | 103 | $1,427 |
| Losartan Potassium | 155 | $1,227 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaBrilinta, Farxiga | $115 | $86,96594 claims |
| PfizerEliquis | $30 | $86,459102 claims |
| Johnson & JohnsonXarelto | $268 | $37,42029 claims |
| NovartisEntresto | $127 | $24,61726 claims |
| Boehringer IngelheimJardiance | $66 | $15,66812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 223 interventional cardiology providers in Arizona.
Other interventional cardiology in Peoria
- Azimuddin KhawajaPeoria$199K
- Rahul SharmaPeoria$195K
- Michael AmponsahPeoria$46K
- Paul SorajjaPhoenix$8.8M
- Thomas WaggonerTucson$4.1M
- Hursh NaikAvondale$2.2M
- Nabil DibGilbert$2.2M
- Timothy ByrnePhoenix$2.1M
- Ashish PershadChandler$1.4M
- Mohamad LazkaniPhoenix$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.